Independent Market Access and Reimbursement Risk Assessment.
Built by former payers, HTA reviewers, and Industry Experts.
Summary Shionogi agreed on October 5, 2026, to acquire IntraBio, a Texas-based rare disease company, for $2 billion in cash. The deal gives Shionogi full control of Aqneursa, a treatment
Summary The White House has announced “most-favored-nation” pricing agreements with 26 pharmaceutical companies over the past year. The stated goal is to bring US drug prices closer to prices paid
Summary The U.S. administration has threatened tariffs of up to 200% on imported generic drugs. Branded medicines have seen limited impact so far. In part, that is because 17 drugmakers
Summary GSK will discontinue camlipixant, the chronic cough treatment it gained through its acquisition of Bellus Health. Two pivotal trials produced conflicting results. One dose worked in one study and
Why this document exists A medicine can be approved by regulators and still fail commercially, because the public bodies and insurers who pay for medicines apply their own, separate test.
Summary Zymeworks agreed to acquire Theravance Biopharma for $929 million, following the failure of ampreloxetine in neurogenic orthostatic hypotension. Consequently, Theravance entered a strategic review that identified its approved portfolio
Summary Ipsen announced the acquisition of Swiss biotech Memo Therapeutics on July 1, 2026. The deal is valued at up to $800 million, with €200 million upfront and more than
Summary Tennessee enacted the FAIR Rx Act, banning pharmacy benefit manager-owned pharmacies from operating in the state. Express Scripts and the PCMA filed separate lawsuits in June 2026 to block
Summary A proposed CMS rule would close a formulation-switch loophole in Medicare’s drug price negotiation program. Merck’s Keytruda QLEX and Bristol Myers Squibb’s Opdivo Qvantig — subcutaneous versions of established
On 9 June 2026, the European Commission published the first Joint Clinical Assessment (JCA) under the EU HTA Regulation. The drug assessed was tovorafenib (Ojemda), an oral RAF inhibitor for